PlumX Metrics
Embed PlumX Metrics

Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration

Diabetes, ISSN: 1939-327X, Vol: 71, Issue: 7, Page: 1591-1596
2022
  • 18
    Citations
  • 0
    Usage
  • 18
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients

Introduction In recent 30 years, the prevalence of diabetes mellitus in China has increased significantly.1,2 The epidemiological survey of diabetes mellitus conducted by the Endocrinology

Article Description

C-peptide declines in type 1 cfabetes, although many long- duration patients retain low, but detectable levels. Histologi- cal analyses confirm that p-cells can remain following type 1 diabetes onset We explored the trends observed in C- peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archi- val Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7-12, ≥13 years) across increasing diabetes durations. The pro- portion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age cyoup (<1-year duration: age <7 years: 18 of 20 [90%], 7-12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1-5 years postdiagnosis: <7 years: 172 of 522 [33%], 7-12 years: 604 of 995 [61 %],≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those cfiagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells<1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7-12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1-5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7-12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β -cell retention and function.

Bibliographic Details

Carr, Alice L J; Inshaw, Jamie R J; Flaxman, Christine S; Leete, Pia; Wyatt, Rebecca C; Russell, Lydia A; Palmer, Matthew; Prasolov, Dmytro; Worthington, Thomas; Hull, Bethany; Wicker, Linda S; Dunger, David B; Oram, Richard A; Morgan, Noel G; Todd, John A; Richardson, Sarah J; Besser, Rachel E J

American Diabetes Association

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know